A Phase 1 interventional study of Nintedanib and Nintedanib in Hepatic Insufficiency, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-01.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hepatic Insufficiency by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Hepatic Insufficiency · Boehringer Ingelheim.
Among the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 12 in phase 1, and was the 6th registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →None of the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim is open now. The open studies under Hepatic Insufficiency, anywhere →
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is above the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 33 across the 13 interventional studies. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to investigate the effect of mild (Child-Pugh A, score 5-6) and moderate (Child-Pugh B, score 7-9) hepatic impairment on the pharmacokinetics, safety and tolerability of nintedanib, in comparison with a control group with normal hepatic function following oral administration of nintedanib as single dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy subjects:
Hepatically impaired patients as determined by a hepatologist/ gastroenterologist:
Exclusion criteria:
Healthy subjects:
Hepatically impaired patients as determined by a hepatologist/gastroenterologist:
Patients with significant diseases other than underlying diagnose of hepatic impairment and concomitant diseases related to it. A significant disease is defined as a disease which in the opinion of the investigator:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with mild hepatic impaired function (Child-Pugh A)
Drug: Nintedanib
Patients with moderate hepatic impaired function (Child-Pugh B)
Drug: Nintedanib
Healthy control subjects
Drug: Nintedanib
Soft gelatine capsule
Soft gelatine capsule
Soft gelatine capsule
AUC (0-inf) of Nintedanib
AUC (0-inf) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 extrapolated to infinity)
Time frame: Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration
Cmax of Nintedanib
Cmax (Maximum measured concentration of the Nintedanib in plasma)
Time frame: Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration
AUC (0-tz) of Nintedanib
AUC (0-tz) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)
Time frame: Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration
Number (%) of Subjects With Drug-related Adverse Events (AEs)
Number (%) of subjects with drug-related Adverse events (AEs)
Time frame: (AEs) during the 'on-treatment' period (from administration of trial medication until the end of the 28-day residual effect period); Up to 29 days
Healthy subjects were to be matched to subjects with hepatic impairment ((Child-Pugh A, score 5 or 6),(Child-Pugh B, score 7 to 9)) by age (±10 years), body weight (±10%), sex, race, and smoking habits (current vs. ex- and never smokers).
| Milestone | Child Pugh A | Child Pugh B | Healthy |
|---|---|---|---|
| Started | 8 | 8 | 17 |
| Completed | 8 | 8 | 17 |
| Not completed | 0 | 0 | 0 |
AUC (0-inf) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 extrapolated to infinity)
| ng*h/mL | Child-Pugh A | Child-Pugh B | Healthy Matched Child-Pugh A | Healthy Matched Child-Pugh B |
|---|---|---|---|---|
| AUC (0-inf) of Nintedanib | 200 ± 87.7 | 674 ± 66.3 | 92.7 ± 58.5 | 77.8 ± 38.2 |
Cmax (Maximum measured concentration of the Nintedanib in plasma)
| ng/mL | Child-Pugh A | Child-Pugh B | Healthy Matched Child-Pugh A | Healthy Matched Child-Pugh B |
|---|---|---|---|---|
| Cmax of Nintedanib | 20.5 ± 68.4 | 59.4 ± 87.0 | 9.25 ± 54.1 | 7.81 ± 49.3 |
AUC (0-tz) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)
| ng*h/mL | Child-Pugh A | Child-Pugh B | Healthy Matched Child-Pugh A | Healthy Matched Child-Pugh B |
|---|---|---|---|---|
| AUC (0-tz) of Nintedanib | 193 ± 89.5 | 652 ± 66.2 | 89.2 ± 59.6 | 74.8 ± 38.9 |
Number (%) of subjects with drug-related Adverse events (AEs)
| percentage of participants | Child-Pugh A | Child-Pugh B | Healthy |
|---|---|---|---|
| Number (%) of Subjects With Drug-related Adverse Events (AEs) | 0.0 | 37.5 | 17.6 |
Collected over AEs during the 'on-treatment' period (from administration of trial medication until the end of the 28-day residual effect period); up to 29 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Child Pugh A | — | 0/8 (0%) | 0/8 (0%) |
| Child Pugh B | — | 0/8 (0%) | 3/8 (37.5%) |
| Healthy | — | 0/17 (0%) | 3/17 (17.6%) |
| Event | Child Pugh A | Child Pugh B | Healthy |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/8 | 1/8 | 0/17 |
| NauseaGastrointestinal disorders | 0/8 | 1/8 | 2/17 |
| PruritusSkin and subcutaneous tissue disorders | 0/8 | 1/8 | 0/17 |
| Skin irritationSkin and subcutaneous tissue disorders | 0/8 | 1/8 | 0/17 |
| VomitingGastrointestinal disorders | 0/8 | 0/8 | 1/17 |
| HeadacheNervous system disorders | 0/8 | 0/8 | 1/17 |
Treated set: The treated set (TS) included all subjects who were dispensed study medication and were documented to have taken atleast one dose of investigational treatment.
| Age, Continuous(years) | Child Pugh A | Child Pugh B | Healthy | Total |
|---|---|---|---|---|
| Mean | 60.6 ± 8.1 | 56.6 ± 6.5 | 57.6 ± 8.4 | 58.1 ± 7.8 |
| Sex: Female, Male(Participants) | Child Pugh A | Child Pugh B | Healthy | Total |
|---|---|---|---|---|
| Female | 3 | 3 | 7 | 13 |
| Male | 5 | 5 | 10 | 20 |
The record gives a start of Jul 2014, a primary completion of Dec 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib